EMX vs. PFE

Last updated Apr 1, 2026

Compare and contrast key facts about EMX Royalty Corporation (EMX) and Pfizer Inc. (PFE).

Performance

EMX vs. PFE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in EMX Royalty Corporation (EMX) and Pfizer Inc. (PFE). The values are adjusted to include any dividend payments, if applicable.

EMX vs. PFE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
EMX EMX Royalty Corporation	0.00%	140.46%	6.79%	-14.29%	-16.74%	-32.24%	104.07%	45.27%	35.95%	-20.08%
PFE Pfizer Inc.	14.66%	0.65%	-2.22%	-41.26%	-10.41%	66.70%	3.07%	-6.91%	24.82%	15.90%

Fundamentals

Market Cap EMX : $454.57M PFE : $159.66B
EPS EMX : $0.04 PFE : $1.36
PE Ratio EMX : 94.44 PFE : 20.61
PEG Ratio EMX : 21.38 PFE : 0.37
PS Ratio EMX : 17.07 PFE : 2.56
PB Ratio EMX : 3.92 PFE : 1.72
Total Revenue (TTM) EMX : $26.63M PFE : $62.58B
Gross Profit (TTM) EMX : $10.56M PFE : $44.01B
EBITDA (TTM) EMX : $18.42M PFE : $15.10B

Returns By Period

EMX

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

PFE

• 1D: 1.12%
• 1M: 1.56%
• YTD: 14.66%
• 6M: 14.02%
• 1Y: 18.86%
• 3Y*: -6.22%
• 5Y*: -0.14%
• 10Y*: 4.32%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

EMX vs. PFE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PFE

PFE Risk / Return Rank: 65
PFE Sharpe Ratio Rank: 67
PFE Sortino Ratio Rank: 61
PFE Omega Ratio Rank: 59
PFE Calmar Ratio Rank: 69
PFE Martin Ratio Rank: 69

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EMX vs. PFE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for EMX Royalty Corporation (EMX) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	EMX	PFE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	0.71	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.01	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.18	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.26	—

Correlation

The correlation between EMX and PFE is 0.05, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

EMX vs. PFE - Dividend Comparison

EMX has not paid dividends to shareholders, while PFE's dividend yield for the trailing twelve months is around 6.13%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
EMX EMX Royalty Corporation	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
PFE Pfizer Inc.	6.13%	6.91%	6.33%	5.70%	3.12%	2.64%	3.92%	3.68%	3.12%	3.53%	3.69%	3.47%

Drawdowns

Drawdown Indicators

	EMX	PFE	Difference
Max Drawdown Largest peak-to-trough decline	—	-58.96%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-12.59%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-58.96%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-58.96%	—
Current Drawdown Current decline from peak	—	-42.75%	—
Average Drawdown Average peak-to-trough decline	—	-17.33%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	6.13%	—

Volatility

Volatility by Period

	EMX	PFE	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	6.75%	—
Volatility (6M) Calculated over the trailing 6-month period	—	18.50%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	26.73%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	25.46%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	23.90%	—

Financials

EMX vs. PFE - Profitability Comparison

The chart below illustrates the profitability comparison between EMX Royalty Corporation and Pfizer Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

EMX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, EMX Royalty Corporation reported a gross profit of 2.53M and revenue of 5.77M. Therefore, the gross margin over that period was 43.8%.

PFE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Pfizer Inc. reported a gross profit of 12.29B and revenue of 17.56B. Therefore, the gross margin over that period was 70.0%.

EMX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, EMX Royalty Corporation reported an operating income of 975.00K and revenue of 5.77M, resulting in an operating margin of 16.9%.

PFE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Pfizer Inc. reported an operating income of 3.69B and revenue of 17.56B, resulting in an operating margin of 21.0%.

EMX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, EMX Royalty Corporation reported a net income of 642.00K and revenue of 5.77M, resulting in a net margin of 11.1%.

PFE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Pfizer Inc. reported a net income of -1.65B and revenue of 17.56B, resulting in a net margin of -9.4%.